Author

Charles P. Barranco

Observed names: C.P. Barranco, Charles Barranco

Institution: Arno Therapeutics (United States)

Observed institutions: Arno Therapeutics (United States), Bexon Clinical Consulting (United States)

OpenAlex ID: A5089192512

Itraconazole treatment of phaeohyphomycosis

1990 · Patricia Kay Sharkey, John R. Graybill, et al. · Journal of the American Academy of Dermatology · 212

A double-blind, randomized, placebo-controlled, dose-finding study of oral pramiconazole in the treatment of pityriasis versicolor

2009 · Jan Faergemann, Gail Todd, et al. · Journal of the American Academy of Dermatology · 18

Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of intravenous infusion of SNS01-T, a first-in-class modulator of eukaryotic translation initiation factor 5A (eIF5A) in patients (pts) with relapsed or refractory B-cell malignancies.

2014 · Michael Craig, William Bensinger, et al. · Journal of Clinical Oncology · 2

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study To Evaluate The Safety and Tolerability Of Intravenous Infusion Of SNS01-T In Patients With Relapsed Or Refractory Multiple Myeloma, Mantle Cell Lymphoma, Or Diffuse Large B Cell Lymphoma

2013 · John A Lust, Charles Barranco, et al. · Blood · 2

Aspergillus and its place in medical mycology

1994 · C.P. Barranco · Medical Mycology · 2

Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.

2017 · Anuradha Jayaram, Karolina Nowakowska, et al. · Journal of Clinical Oncology · 1

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies

2014 · David S. Siegel, Andrew McDonald, et al. · Blood · 1

Clinical Data Acquisition using Five-Part NCR Case Record forms and Overnight Delivery

1995 · Charles P. Barranco · Drug Information Journal · 1

Validation of a population pharmacokinetic (PPK) model for onapristone (ONA) in patients (pts) with cancer: Analysis of 2 clinical trials.

2016 · Keyvan Rezai, Samuel Huguet, et al. · Journal of Clinical Oncology

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study

2014 · Alice S Bexon, Michael Craig, et al. · Blood

Phase 1b/2a Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma.

2012 · John A Lust, Saad Z Usmani, et al. · Blood

Phase I/II open-label, multiple-dose, dose-escalation study to evaluate the safety and tolerability of SNS01T administered by intravenous infusion in patients with relapsed or refractory multiple myeloma.

2012 · John Anthony Lust, Charles Barranco, et al. · Journal of Clinical Oncology

Works count: 12

Citation count: 239

H-index: 2

I10-index: 2